<DOC>
	<DOCNO>NCT00026364</DOCNO>
	<brief_summary>Phase I trial study effectiveness ZD 1839 combine irinotecan , leucovorin , fluorouracil treat patient locally advance , locally recurrent , metastatic colorectal cancer . Biological therapy ZD 1839 may interfere growth tumor cell slow growth tumor . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining ZD 1839 combination chemotherapy may kill tumor cell .</brief_summary>
	<brief_title>ZD 1839 Plus Combination Chemotherapy Treating Patients With Locally Advanced , Locally Recurrent , Metastatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ZD 1839 combination irinotecan , leucovorin calcium , fluorouracil patient locally advance , locally recurrent , metastatic colorectal cancer . II . Determine dose-limiting toxicity regimen patient . III . Determine pharmacokinetics regimen patient . IV . Determine objective response rate patient treat regimen . V. Correlate epidermal growth factor receptor expression probability objective tumor response patient . OUTLINE : This multicenter , dose-escalation study ZD 1839 . Patients receive oral ZD 1839 daily . Beginning day 15 , patient receive irinotecan IV 90 minute , leucovorin calcium IV 15 minute , fluorouracil IV weekly week 1-2 . Treatment repeat every 3 week absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos ZD 1839 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , 10 additional patient accrue receive treatment MTD . Patients follow 30 day .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma colon rectum Locally advance , locally recurrent , metastatic disease Not curable surgery and/or amenable radiotherapy curative intent Histological cytological confirmation metastatic cancer require patient prior surgically resect colorectal cancer 5 year elapse primary surgery development metastatic disease OR primary cancer stage I II Prior adjuvant therapy fluorouracil immunotherapy resect stage II , III , IV disease allow Measurable disease No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : More 12 week Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin normal AST/ALT great 5 time upper limit normal Renal : Creatinine normal Cardiovascular : No uncontrolled high blood pressure No unstable angina No symptomatic congestive heart failure No myocardial infarction within past 6 month No serious uncontrolled cardiac arrhythmia No New York Heart Association class III IV heart disease Other : No active uncontrolled infection No predisposing colonic small bowel disorder uncontrolled symptom indicate 3 loose stool daily patient without colostomy ileostomy No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer adequately treat noninvasive carcinoma No concurrent medical psychiatric condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : At least 12 month since prior immunotherapy Chemotherapy : At least 12 month since prior fluorouracil No prior chemotherapy advanced colorectal cancer No prior irinotecan Radiotherapy : No prior radiotherapy 15 % bone marrow At least 4 week since prior major radiotherapy ( e.g. , chest bone palliative radiotherapy ) No concurrent radiotherapy Surgery : At least 4 week since prior major surgery ( e.g. , laparotomy ) recover At least 2 week since prior minor surgery recover No concurrent ophthalmic surgery Other : No prior ZD 1839 No concurrent investigational commercial agent therapy malignancy No concurrent combination antiretroviral therapy HIV No concurrent oral retinoids No concurrent prochlorperazine day irinotecan administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2002</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>